Bliss GVS Pharma Share Price Target From 2024 to 2030: Bliss GVS Pharma is one of the well-emerged Indian pharmaceutical companies in the health sector. It has a product portfolio that includes antifungal, antibacterial, antimalarial, and probiotic drugs. Its steady growth curve and innovations have made it a strong competitor in the pharmaceutical sector. This article focuses on Bliss GVS Pharma Share Price Target From 2024 to 2030 by understanding the factors affecting its market movement.
Company Summary
Bliss GVS Pharma was established in the year 1984. Headquartered at Mumbai, India, it concentrates on research and development as well as affordable healthcare solutions for the global market. The company operates in over 60 countries across Asia, Africa, and Latin America. Bliss GVS Pharma has a niche in fast-dissolving oral thin films, suppositories, and pessaries, where it has an unchallenged leadership position in delivery technologies.
Key Metrics For Bliss GVS Pharma Share Price
- Market Capitalization: ₹1,570 Crores
- P/E Ratio: 28.34
- Dividend Yield: 0.30%
- 52 Week High: ₹172.42
- 52 Week Low: ₹92.15
Bliss GVS Pharma Share Price
The company has an amazing ascending trend. Its stock is trading at ₹167.90 now with 18.45% YTD growth. The reason is business growth, new drug formulations, and the improvement in financials.
Shareholding Pattern For Bliss GVS Pharma Share Price
- Promoters: At 34.82% have decreased from 34.90%
- Retail and Others: 46.49%
- Foreign Institutions: At 12.13% have declined from 13.24%
- Other Domestic Institutions: 6.56%
Bliss GVS Pharma Share Price Predictions (2024-2030)
| YEAR | SHARE PRICE TARGET |
| 2024 | ₹175 |
| 2025 | ₹255 |
| 2026 | ₹342 |
| 2027 | ₹425 |
| 2028 | ₹512 |
| 2029 | ₹602 |
| 2030 | ₹695 |
2024: Bliss GVS Pharma Share Price Target ₹175
Revenue growth will be maintained at the same pace. Emerging markets growth will sustain in the new markets. All these will help take the share price of the company to ₹175 at the end of 2024. The sustained new product launches and international tie-ups will keep the business humming.
2025: Bliss GVS Pharma Share Price Target ₹255
Operational efficiency, in terms of higher adoption rates of innovative drug delivery products, will push the share price to ₹255 by 2025. Revenue from partnerships with global health service providers will increase in the company.
2026: Bliss GVS Pharma Share Price Target ₹342
Bliss GVS Pharma will expand to a share price of ₹342 in 2026. This expansion is driven by improved R&D capabilities and entry into high-growth markets, including the Middle East.
2027: Bliss GVS Pharma Share Price Target ₹425
The share price of the company will be ₹425 in the year 2027 since it will tap unpenetrated markets and will develop its portfolio in chronic disease drugs.
2028: Bliss GVS Pharma Share Price Target ₹512
The share price of Bliss GVS Pharma will touch ₹512 in the year 2028. Here, the main reason will be higher-margin sales with entry into wellness categories, which will drive it to rise.
2029: Bliss GVS Pharma Share Price Target ₹602
Having a strong global footprint and rich product pipeline shall see the share price touch ₹602 in 2029. Key acquisitions and partnerships shall take it to this stage.
2030: Bliss GVS Pharma Share Price Target ₹695
The long-term share price target of ₹695 in 2030 would reflect the sustainability of the company in innovation, improving profit, and value creation for the shareholders. Bliss GVS Pharma would have well established its position as a global pharmaceutical company by this time.
Drivers behind Bliss GVS Pharma Share Price Growth
- Growth in International Markets: Strong business diversified into emerging markets has brought growth and revenue stability.
- Innovative Offerings: Focus on innovations pertaining to drug delivery and cost-effective health care options have only added to its comparative advantage
- Shareholding: While promoters as well as FIIs shareholding declined marginally, increased retail participation and rise in no. of FII investors from 27 to 39 speaks a lot about growing interest in its stock.
- Operational Performance: High on researches, in manufacturing: yields high margins.
- Dividend Policies: The dividend yield is low at 0.30%. It reflects the Company’s desire for value return to its shareholders
Risks For Bliss GVS Pharma Share Price
- Regulatory Changes: Tougher regulatory policies by major markets may inhibit the launches and growths of revenues.
- Currency Risk: The company is highly vulnerable to currency fluctuations as most revenue streams belong to international markets.
- Competition: The pharmaceutical industry is very competitive with persistent pressure on pricing and innovation.
FAQS relating to Bliss GVS Pharma Share Price
Q1: What is the Current Bliss GVS Pharma Share Price?
The current stock price lies in Rs167.90, which has gone up to 18.45 percent year over year.
Q2. Why did the promoter holding decline in September 2024?
The promoter holding declines a little from 34.90 percent to 34.82%, and this might be the due effect of some strategic moves or simply reallocation of the same.
Q3: How many FIIs are investing in Bliss GVS Pharma?
The count of FII investors is reported at 39 with an increment of 27 in the last quarter September 2024, reflecting the upward trend of interest from foreign investors.
Q4: Where are long-term growth prospects?
The company will benefit from innovative drug delivery technology, growth and expansion through strategic partnerships to continue to enjoy high-growth markets driving long-term growth.
Q5: Does Bliss GVS Pharma pay out dividend or not?
Yes, although the dividend yield is very low at 0.30% as of now since the company prefers to retain earnings to fuel further growth.
Q6: What is the market capitalization of the company?
The market capitalization for Bliss GVS Pharma stands at ₹1,570 crores.
Q7: What are the risks that accompany investment in Bliss GVS Pharma?
The risks include regulatory hurdles, exchange rates fluctuations, and highly competitive pharmaceutical industry.
Bliss GVS Pharma has shown constant and consistent growth fundamentals. It is good for long-term benefits because it has projected the Bliss GVS Pharma Share Price target of ₹695 by the year 2030. It has innovation, globalization, and performance excellence, putting it well on the track to becoming a strong player in the pharmaceutical industry. But investment and market risks have to be viewed before investing.
